BACKGROUND/AIM: Esophagitis is a significant toxicity of radiation therapy for lung cancer. In this study, reduction of irradiation esophagitis in mice, by orally administered p53/Mdm2/Mdm4 inhibitor, BEB55, or the GS-nitroxide, JP4-039, was evaluated. MATERIALS AND METHODS: BEB55 or JP4-039 in F15 (liposomal) formulation was administered intraesophageally to C57BL/6 mice prior to thoracic irradiation of 29 Gy × 1 or 11.5 Gy × 4 thoracic irradiation. Progenitor cells were sorted from excised esophagus, and nitroxide was quantified, by electron paramagnetic resonance (EPR). Mice with Lewis lung carcinoma (3LL) orthotopic lung tumors were treated with BEB55 or JP4-039 prior to 20 Gy to determine if the drugs would protect the tumor cells from radiation. RESULTS: Intraesophageal BEB55 and JP4-039 compared to formulation alone increased survival after single fraction (p=0.0209 and 0.0384, respectively) and four fraction thoracic irradiation (p=0.0241 and 0.0388, respectively). JP4-039 was detected in esophagus, liver, bone marrow, and orthotopic Lewis lung carcinoma (3LL) tumor. There was no significant radiation protection of lung tumors by BEB55 or JP4-039 compared to formulation only as assessed by survival (p=0.3021 and 0.3693, respectively). Thus, BEB55 and JP4-039 safely ameliorate radiation esophagitis in mice.
BACKGROUND/AIM: Esophagitis is a significant toxicity of radiation therapy for lung cancer. In this study, reduction of irradiation esophagitis in mice, by orally administered p53/Mdm2/Mdm4 inhibitor, BEB55, or the GS-nitroxide, JP4-039, was evaluated. MATERIALS AND METHODS:BEB55 or JP4-039 in F15 (liposomal) formulation was administered intraesophageally to C57BL/6 mice prior to thoracic irradiation of 29 Gy × 1 or 11.5 Gy × 4 thoracic irradiation. Progenitor cells were sorted from excised esophagus, and nitroxide was quantified, by electron paramagnetic resonance (EPR). Mice with Lewis lung carcinoma (3LL) orthotopic lung tumors were treated with BEB55 or JP4-039 prior to 20 Gy to determine if the drugs would protect the tumor cells from radiation. RESULTS: Intraesophageal BEB55 and JP4-039 compared to formulation alone increased survival after single fraction (p=0.0209 and 0.0384, respectively) and four fraction thoracic irradiation (p=0.0241 and 0.0388, respectively). JP4-039 was detected in esophagus, liver, bone marrow, and orthotopic Lewis lung carcinoma (3LL) tumor. There was no significant radiation protection of lung tumors by BEB55 or JP4-039 compared to formulation only as assessed by survival (p=0.3021 and 0.3693, respectively). Thus, BEB55 and JP4-039 safely ameliorate radiation esophagitis in mice.
Authors: Yunyun Niu; Hongmei Shen; Michael Epperly; Xichen Zhang; Suhua Nie; Shaonan Cao; Joel S Greenberger Journal: In Vivo Date: 2005 Nov-Dec Impact factor: 2.155
Authors: Ahmad A Tarhini; Chandra P Belani; James D Luketich; Athanassios Argiris; Suresh S Ramalingam; William Gooding; Arjun Pennathur; Daniel Petro; Kevin Kane; Denny Liggitt; Tony Championsmith; Xichen Zhang; Michael W Epperly; Joel S Greenberger Journal: Hum Gene Ther Date: 2011-02-02 Impact factor: 5.695
Authors: Jean-Claude M Rwigema; Barbara Beck; Wei Wang; Alexander Doemling; Michael W Epperly; Donna Shields; Julie P Goff; Darcy Franicola; Tracy Dixon; Marie-Céline Frantz; Peter Wipf; Yulia Tyurina; Valerian E Kagan; Hong Wang; Joel S Greenberger Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-13 Impact factor: 7.038
Authors: Michael W Epperly; Julie P Goff; Song Li; Xiang Gao; Peter Wipf; Tracy Dixon; Hong Wang; Darcy Franicola; Hongmei Shen; Jean-Claude M Rwigema; Valerian Kagan; Mark Bernard; Joel S Greenberger Journal: In Vivo Date: 2010 Nov-Dec Impact factor: 2.155
Authors: Jianfei Jiang; Detcho A Stoyanovsky; Natalia A Belikova; Yulia Y Tyurina; Qing Zhao; Muhammad A Tungekar; Valentyna Kapralova; Zhentai Huang; Arlan H Mintz; Joel S Greenberger; Valerian E Kagan Journal: Radiat Res Date: 2009-12 Impact factor: 2.841
Authors: Jianfei Jiang; Natalia A Belikova; Adam T Hoye; Qing Zhao; Michael W Epperly; Joel S Greenberger; Peter Wipf; Valerian E Kagan Journal: Int J Radiat Oncol Biol Phys Date: 2008-03-01 Impact factor: 7.038
Authors: D J Kanter; M B O'Brien; X-H Shi; T Chu; T Mishima; S Beriwal; M W Epperly; P Wipf; J S Greenberger; Y Sadovsky Journal: Placenta Date: 2014-01-02 Impact factor: 3.481
Authors: Marie-Céline Frantz; Erin M Skoda; Joshua R Sacher; Michael W Epperly; Julie P Goff; Joel S Greenberger; Peter Wipf Journal: Org Biomol Chem Date: 2013-07-07 Impact factor: 3.876
Authors: Michael W Epperly; Renee Fisher; Xichen Zhang; Wen Hou; Donna Shields; Peter Wipf; Hong Wang; Stephanie Thermozier; Joel S Greenberger Journal: In Vivo Date: 2020 Jan-Feb Impact factor: 2.155
Authors: Joel S Greenberger; David Clump; Valerian Kagan; Hülya Bayir; John S Lazo; Peter Wipf; Song Li; Xiang Gao; Michael W Epperly Journal: Front Oncol Date: 2012-01-13 Impact factor: 6.244